ALK Positive Lung Cancer Treatment; ALK Inhibitors Are Effective For Advanced ALK-Positive NSCLC

 

ALK Positive Lung Cancer Treatment

Some lung cancers involve a gene mutations that affect how quickly the cancer grows. The ALK (anaplastic lymphoma kinase) mutation is one of those gene changes. ALK positive lung cancer treatment is used for people suffering from lung cancer with ALK mutation. Among the many different mutations, the ALK is one of the more treatable mutation as it often responds dramatically to targeted therapy. It responds very well to a group of targeted drugs called ALK inhibitors. Chemotherapy and other drugs also work against ALK positive lung cancer.

ALK positive lung cancer occurs mainly in patients with non-small-cell lung cancer (NSCLC). Around 5% of people with NSCLC have the ALK-positive kind. Worldwide, ALK-positive lung cancer causes around 72,000 new cases of lung cancer and 64,000 deaths each year. Stage IV is the most advanced stage, which means the disease has spread to distant parts of the body, such as the brain and bones. Lung cancer is the third most common cancer in the United States.

According to the American Cancer Society, around 84% of all lung cancers are NSCLC. ALK inhibitors widely used for ALK positive lung cancer treatment. The U.S. Food and Drug Administration (USFDA) has also approved some ALK inhibitors for the treatment of ALK positive lung cancer. In 2020, FDA approved brigatinib for adult patients with ALK-positive NSCLC. Moreover, FDA approved Lorbrena (lorlatinib) as a first-line treatment for patients with ALK-positive non-small cell lung cancer.

When ALK fuses or joins with another gene and causes lung cancer, a patient is said to be ALK-positive. Stage IV patients are often prescribed a pill called ALK-inhibitor or a tyrosine kinase inhibitor (TKI). Lorlatinib (Lorbrena), Brigatinib (Alunbrig), Alectinib (Alecensa), Ceritinib (Zykadia), Crizotinib (Xalkori), and ALK-Inhibitors are some of the ALK-inhibitors commonly used for ALK positive lung cancer treatment. In the last few years, a flurry of new and more potent ALK inhibitors has emerged for the treatment of ALK-positive NSCLC.


Comments

Popular posts from this blog

Light Linear Alpha Olefins Are Produces through Oligomerization of Ethylene and by Fischer-Tropsch Synthesis

Cervical Cancer Diagnostic Tests have become highly sophisticated with accurate diagnosis for effective treatment

Beta Glucan-based products have been shown to be effective in lowering cholesterol and preventing heart disease